NICE Recommends Celgene’s Pancreatic Cancer Treatment Abraxane for NHS Use

LW Newsfeed
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Celgene’s nab-paclitaxel as a life-extending treatment for patients with progressive pancreatic cancer.
Also known as abraxane, nab-paclitaxel will be routinely available for eligible patients on the National Health Service (NHS) England. Read more . . .

image_printPrint Page